Biomaterial Database

The influence of vinblastine treatment on the formation of radiation-induced micronuclei in mouse bone marrow. 1994

G C Jagetia, and P S Jacob

Department of Radiobiology, Kasturba Medical College, Manipal, India.

The combined effects of vinblastine sulphate (VBL) and gamma radiation treatments on the induction of micronuclei in polychromatic erythrocytes (MPCE) and normochromatic erythrocytes (MNCE) and changes in polychromatic/normochromatic erythrocyte ratio (P/N ratio) in mouse bone marrow, were studied. Compared to double distilled water (DDW) injected controls, 0.05 mg/kg b.wt. of vinblastine alone significantly increased the frequency of MPCE and MNCE. When VBL was administered before exposure to various doses of gamma radiation the frequency of micronuclei (MPCE and MNCE) increased with the increasing radiation dose up to a dose of 4 Gy, but this increase levelled off at 3 to 4 Gy irradiation. The frequency of MPCE was found to be significantly lower at 3 and 4 Gy radiation when compared to the DDW+irradiated group. A significant dose dependent decline in the P/N ratio was observed in the DDW+irradiated group. VBL treatment before irradiation resulted in a more significant decline in the P/N ratio than that of DDW+irradiated group. The formation of micronuclei (MPCE and MNCE) increased from 8 h post-exposure and continued to increase up to 28 h. There was a sharp decline in the frequency of micronuclei (MPCE and MNCE) at 32 h post-irradiation, in both DDW + 1 Gy irradiated and VBL + 1 Gy irradiated groups; then it declined gradually up to 72 h post-exposure without restoration to normal level. The P/N ratio declined with time in all three groups (VBL alone, DDW+irradiation, and VBL+irradiation) without restoration to normal level up to 72 h post-treatment, except in the DDW+irradiated group, where it was normal.

UI	MeSH Term	Description	Entries
D008807	Mice, Inbred BALB C	An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research.	BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D001853	Bone Marrow	The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.	Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004307	Dose-Response Relationship, Radiation	The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.	Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D004912	Erythrocytes	Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN.	Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005260	Female		Females
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D013997	Time Factors	Elements of limited time intervals, contributing to particular results or situations.	Time Series,Factor, Time,Time Factor
D014747	Vinblastine	Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)	Vincaleukoblastine,Cellblastin,Lemblastine,Velban,Velbe,Vinblastin Hexal,Vinblastina Lilly,Vinblastine Sulfate,Vinblastinsulfat-Gry,Sulfate, Vinblastine
D016609	Neoplasms, Second Primary	Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.	Neoplasms, Metachronous,Neoplasms, Metachronous Second Primary,Neoplasms, Therapy-Related,Neoplasms, Treatment-Related,Second Malignancy,Second Neoplasm,Second Primary Neoplasms,Therapy-Associated Neoplasms,Therapy-Related Cancer,Treatment-Associated Neoplasms,Treatment-Related Cancer,Cancer, Second Primary,Metachronous Neoplasms,Metachronous Second Primary Neoplasms,Neoplasms, Therapy-Associated,Neoplasms, Treatment-Associated,Second Cancer,Second Primary Neoplasms, Metachronous,Therapy-Associated Cancer,Therapy-Related Neoplasms,Treatment-Associated Cancer,Treatment-Related Neoplasms,Cancer, Second,Cancer, Therapy-Associated,Cancer, Therapy-Related,Cancer, Treatment-Associated,Cancer, Treatment-Related,Cancers, Second,Cancers, Second Primary,Cancers, Therapy-Associated,Cancers, Therapy-Related,Cancers, Treatment-Associated,Cancers, Treatment-Related,Malignancies, Second,Malignancy, Second,Metachronous Neoplasm,Neoplasm, Metachronous,Neoplasm, Second,Neoplasm, Second Primary,Neoplasm, Therapy-Associated,Neoplasm, Therapy-Related,Neoplasm, Treatment-Associated,Neoplasm, Treatment-Related,Neoplasms, Second,Neoplasms, Therapy Associated,Neoplasms, Therapy Related,Neoplasms, Treatment Associated,Neoplasms, Treatment Related,Second Cancers,Second Malignancies,Second Neoplasms,Second Primary Cancer,Second Primary Cancers,Second Primary Neoplasm,Therapy Associated Cancer,Therapy Associated Neoplasms,Therapy Related Cancer,Therapy Related Neoplasms,Therapy-Associated Cancers,Therapy-Associated Neoplasm,Therapy-Related Cancers,Therapy-Related Neoplasm,Treatment Associated Cancer,Treatment Associated Neoplasms,Treatment Related Cancer,Treatment Related Neoplasms,Treatment-Associated Cancers,Treatment-Associated Neoplasm,Treatment-Related Cancers,Treatment-Related Neoplasm
D048629	Micronuclei, Chromosome-Defective	Defective nuclei produced during the TELOPHASE of MITOSIS or MEIOSIS by lagging CHROMOSOMES or chromosome fragments derived from spontaneous or experimentally induced chromosomal structural changes.	Chromosome-Defective Micronuclei,Genotoxicant-Induced Micronuclei,Micronuclei, Genotoxicant-Induced,Micronucleus, Chromosome-Defective,Chromosome Defective Micronuclei,Chromosome-Defective Micronucleus,Genotoxicant Induced Micronuclei,Genotoxicant-Induced Micronucleus,Micronuclei, Chromosome Defective,Micronuclei, Genotoxicant Induced,Micronucleus, Chromosome Defective,Micronucleus, Genotoxicant-Induced